Neuronal ceroid lipofuscinosis: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{SI}} | |||
{{Infobox medical condition | |||
| name = Neuronal ceroid lipofuscinosis | |||
| image = [[File:Lipofuscin_neuro.jpg|250px]] | |||
| caption = Microscopic image of lipofuscin accumulation in neurons | |||
| synonyms = Batten disease, CLN disease | |||
| field = [[Neurology]], [[Genetics]] | |||
| symptoms = [[Seizures]], [[vision loss]], [[cognitive decline]], [[motor dysfunction]] | |||
| onset = Childhood, but can vary depending on the type | |||
| duration = Progressive | |||
| causes = [[Genetic mutation]] | |||
| risks = Family history | |||
| diagnosis = [[Genetic testing]], [[MRI]], [[EEG]], [[skin biopsy]] | |||
| differential = [[Other neurodegenerative disorders]] | |||
| treatment = Symptomatic management, [[gene therapy]] (experimental) | |||
| prognosis = Poor, progressive neurodegeneration | |||
| frequency = Rare, varies by type | |||
}} | |||
[[File:Mannose-6-phosphate.svg|Structure of Mannose-6-phosphate|left|thumb]] | |||
[[File:Flupirtine.svg|Chemical structure of Flupirtine|left|thumb]] | |||
'''Neuronal ceroid lipofuscinosis''' (NCL) is a group of [[autosomal recessive]] [[neurodegenerative disorder]]s, which are collectively classified under the broader category of [[lysosomal storage disease]]. The NCLs are characterized by the accumulation of a specific type of lipid-protein complex, known as [[lipofuscin]], within the cells of the body, particularly the neurons. | '''Neuronal ceroid lipofuscinosis''' (NCL) is a group of [[autosomal recessive]] [[neurodegenerative disorder]]s, which are collectively classified under the broader category of [[lysosomal storage disease]]. The NCLs are characterized by the accumulation of a specific type of lipid-protein complex, known as [[lipofuscin]], within the cells of the body, particularly the neurons. | ||
==Etiology== | ==Etiology== | ||
The NCLs are caused by mutations in various genes, which lead to the production of defective proteins. These proteins are involved in the normal functioning of the [[lysosome]], a cellular organelle responsible for the breakdown and recycling of cellular waste products. The defective proteins result in the accumulation of lipofuscin within the lysosomes, leading to cell death and the clinical manifestations of the disease. | The NCLs are caused by mutations in various genes, which lead to the production of defective proteins. These proteins are involved in the normal functioning of the [[lysosome]], a cellular organelle responsible for the breakdown and recycling of cellular waste products. The defective proteins result in the accumulation of lipofuscin within the lysosomes, leading to cell death and the clinical manifestations of the disease. | ||
==Clinical Features== | ==Clinical Features== | ||
The clinical features of the NCLs vary depending on the specific type of NCL, but generally include progressive [[neurological]] deterioration, [[seizure]]s, [[visual impairment]], and [[motor dysfunction]]. The onset of symptoms can occur at any age, from infancy to adulthood. | The clinical features of the NCLs vary depending on the specific type of NCL, but generally include progressive [[neurological]] deterioration, [[seizure]]s, [[visual impairment]], and [[motor dysfunction]]. The onset of symptoms can occur at any age, from infancy to adulthood. | ||
==Diagnosis== | ==Diagnosis== | ||
The diagnosis of NCL is based on the clinical features, [[genetic testing]], and the presence of characteristic autofluorescent lipofuscin deposits in tissue samples. | The diagnosis of NCL is based on the clinical features, [[genetic testing]], and the presence of characteristic autofluorescent lipofuscin deposits in tissue samples. | ||
==Treatment== | ==Treatment== | ||
There is currently no cure for the NCLs. Treatment is supportive and aimed at managing the symptoms of the disease. | There is currently no cure for the NCLs. Treatment is supportive and aimed at managing the symptoms of the disease. | ||
==Prognosis== | ==Prognosis== | ||
The prognosis for individuals with NCL is generally poor, with most individuals dying within a few years of diagnosis. | The prognosis for individuals with NCL is generally poor, with most individuals dying within a few years of diagnosis. | ||
==See Also== | ==See Also== | ||
* [[Batten disease]] | * [[Batten disease]] | ||
* [[Lysosomal storage disease]] | * [[Lysosomal storage disease]] | ||
* [[Neurodegenerative disorder]] | * [[Neurodegenerative disorder]] | ||
[[Category:Neurodegenerative disorders]] | [[Category:Neurodegenerative disorders]] | ||
[[Category:Lysosomal storage diseases]] | [[Category:Lysosomal storage diseases]] | ||
[[Category:Autosomal recessive disorders]] | [[Category:Autosomal recessive disorders]] | ||
{{stub}} | {{stub}} | ||
Latest revision as of 22:07, 9 April 2025
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC
| Neuronal ceroid lipofuscinosis | |
|---|---|
| |
| Synonyms | Batten disease, CLN disease |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Seizures, vision loss, cognitive decline, motor dysfunction |
| Complications | N/A |
| Onset | Childhood, but can vary depending on the type |
| Duration | Progressive |
| Types | N/A |
| Causes | Genetic mutation |
| Risks | Family history |
| Diagnosis | Genetic testing, MRI, EEG, skin biopsy |
| Differential diagnosis | Other neurodegenerative disorders |
| Prevention | N/A |
| Treatment | Symptomatic management, gene therapy (experimental) |
| Medication | N/A |
| Prognosis | Poor, progressive neurodegeneration |
| Frequency | Rare, varies by type |
| Deaths | N/A |
Neuronal ceroid lipofuscinosis (NCL) is a group of autosomal recessive neurodegenerative disorders, which are collectively classified under the broader category of lysosomal storage disease. The NCLs are characterized by the accumulation of a specific type of lipid-protein complex, known as lipofuscin, within the cells of the body, particularly the neurons.
Etiology[edit]
The NCLs are caused by mutations in various genes, which lead to the production of defective proteins. These proteins are involved in the normal functioning of the lysosome, a cellular organelle responsible for the breakdown and recycling of cellular waste products. The defective proteins result in the accumulation of lipofuscin within the lysosomes, leading to cell death and the clinical manifestations of the disease.
Clinical Features[edit]
The clinical features of the NCLs vary depending on the specific type of NCL, but generally include progressive neurological deterioration, seizures, visual impairment, and motor dysfunction. The onset of symptoms can occur at any age, from infancy to adulthood.
Diagnosis[edit]
The diagnosis of NCL is based on the clinical features, genetic testing, and the presence of characteristic autofluorescent lipofuscin deposits in tissue samples.
Treatment[edit]
There is currently no cure for the NCLs. Treatment is supportive and aimed at managing the symptoms of the disease.
Prognosis[edit]
The prognosis for individuals with NCL is generally poor, with most individuals dying within a few years of diagnosis.
